Agoracom Blog

Fairmont (TSX-V: FMR) Receives Short Extension For Grabasa Acquisition $FMR.ca

Posted by AGORACOM-JC at 11:40 AM on Wednesday, February 22nd, 2017

  • Received an extension to complete the payment for Granitos de Badajoz  until March 8, 2017 from the Spanish Court in Badajo
  • “We have been working diligently with a European based funding group and they are in the final stages of completing the necessary documentation,” states Michael Dehn, President and CEO of Fairmont Resources…”

VANCOUVER, BRITISH COLUMBIA–(Feb. 22, 2017) – Fairmont Resources Inc. (“Fairmont”) (TSX VENTURE:FMR) is pleased to announce it has received an extension to complete the payment for Granitos de Badajoz (“Grabasa”) until March 8, 2017 from the Spanish Court in Badajoz.

“We have been working diligently with a European based funding group and they are in the final stages of completing the necessary documentation,” states Michael Dehn, President and CEO of Fairmont Resources. “While there can be no guarantee of success until this process is completed, this short extension was required to secure the Grabasa assets while finalizing the required logistics and paperwork for financing.”

Upon receipt of clearance documentation Fairmont will provide an update to all stakeholders, expected to be in less than a week, on the status of funding for Grabasa.

About Fairmont Resources Inc.

Fairmont Resources Inc. is a rapidly growing industrial mineral and dimensional stone company trading on the Toronto Venture Exchange symbol FMR.

Fairmont’s Quebec properties cover numerous occurrences of high-grade titaniferous magnetite with vanadium, with the Buttercup property having a permit to quarry dense aggregate. Where these occurrences have been tested they have display exceptional uniformity with respect to grade. Fairmont also controls three quartz/quartzite properties, with the Forestville property having independent end user testing confirming the suitability of quartzite from Forestville for Ferro Silicon production. Fairmont is also in the process of acquiring the assets of Granitos de Badajoz (GRABASA) in Spain which includes 23 quarries and a 40,000 square metre granite finishing facility that has produced finished granite installed across Europe.

On behalf of the Board of Directors,

Michael A. Dehn, President and CEO, Fairmont Resources Inc.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Fairmont cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Fairmont’s control. Such factors include, among other things: risks and uncertainties relating to Fairmont’s ability to complete the proposed private placement financing, limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Fairmont undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Michael A. Dehn
President and CEO, Fairmont Resources Inc.
647-477-2382
michael@fairmontresources.ca
www.fairmontresources.ca

Doren Quinton
President QIS Capital
250-377-1182
info@smallcaps.ca
www.smallcaps.ca

 

Chile’s SQM sees 8-10% growth in lithium demand this year $NAM.ca $DGO.ca $BFF.ca $SX.ca $FMR.ca

Posted by AGORACOM-JC at 11:22 AM on Wednesday, February 22nd, 2017
  • “The prices in the lithium market and the growth in demand have been quite relevant in recent years. We expect growth in demand for this product of between 8 and 10 percent,” Illanes said.

Feb 19 Chile’s SQM expects demand for lithium to grow between 8 percent and 10 percent this year and is working to improve financial performance by 2020, an executive told local paper El Mercurio on Sunday.

SQM, one of the world’s biggest producers of lithium and iodine, has been trying to consolidate its position with investments abroad.

In 2020 SQM expects annual earnings before interest, taxes, depreciation and amortization (EBITDA) of $1 billion. Currently quarterly EBITDA is less than $200 million, Gerardo Illanes, vice president of finances, told the newspaper.

“The prices in the lithium market and the growth in demand have been quite relevant in recent years. We expect growth in demand for this product of between 8 and 10 percent,” Illanes said.

SQM plans to invest $100 million to increase its production capacity this year, which combined with its capital injection in Argentina would lead to a total investment of around $300 million, he said.

Illanes said SQM would not have a problem financing its projects although he did not rule out tapping debt markets. (Reporting by Fabián Andrés Cambero; Writing by Caroline Stauffer; Editing by Jeffrey Benkoe)

Source: http://www.reuters.com/article/sqm-demand-idUSL1N1G407H

Tartisan Announces Signing of a LOI for the Purchase of the Don Pancho Zinc-Lead-Silver Property in Peru $TTC.ca

Posted by AGORACOM-JC at 8:03 AM on Wednesday, February 22nd, 2017

Tartisan logo copy

  • letter of intent with Duran Ventures Inc. (V-DRV) for the purchase of the Don Pancho zinc-lead-silver property in Peru
  • Agreement with Duran to acquire 100% of the Don Pancho polymetallic zinc-lead-silver project located in the Department of Lima Peru, 110 kilometers north-northeast of Lima, comprising one concession of 600 hectares

Toronto, Ontario (FSCwire)Tartisan Resources Corp. (CSE: TTC) (“Tartisan”, or the “Company”) is pleased to announce the signing of a letter of intent with Duran Ventures Inc. (V-DRV) ( “Duran”) for the purchase of the Don Pancho zinc-lead-silver property in Peru.

Letter of Intent

Tartisan Resources Corp. has entered into an agreement with Duran to acquire 100% of the Don Pancho polymetallic zinc-lead-silver project located in the Department of Lima Peru, 110 kilometers north-northeast of Lima, comprising one concession of 600 hectares and is the subject of a NI 43-101 compliant Report prepared in December 2014 available for viewing on SEDAR.

The project is located in a prolific polymetallic mineral belt in central Peru with several operating mines in the area including the world class Iscaycruz and Yauliyacu polymetallic mines operated by Glencore-Xtrata Plc located 50 kilometers to the north-northwest. Trevali Mining Corporation’s Santander silver-lead- zinc mine is located 9 kilometers to the east and Buenaventura’s silver-lead-zinc Uchucchacua mine is located 63 kilometers to the north, (10 million ounces of silver produced in 2011). Infrastructure is considered excellent with ready access and a power line crossing the property en route to the Santander mine.

Don Pancho Project

Previous exploration on the property included an extensive surface mapping and sampling program, geophysics and a 2000 metre diamond drilling program of 6 holes conducted by a private Peruvian company.

Mapping and sampling shows an extensive NNW-SSE trending breccia zone measuring over 800 metres in length and 150 to 200 metres in width. There are numerous old workings and underground drifts located within this zone. The 2014 diamond drilling program shows large intersections of polymetallic mineralization, including 40 metres of 0.88% Zn, 0.40% Pb and 7.7 g/t Ag, 22.65 metres of 1.00% Zn, 0.26% Pb and 6.85 g/t Ag and 1.15 metres of 4.38% Zn, 3.25% Pb and 61.1 g/t Ag, (see Duran’s Press Release September 2, 2014). Surface sampling from the previous operator has revealed very interesting values, including 13.9 metres of 28.1 g/t Ag, 2.43% Pb, and 2.42% Zn, 2.8 metres of 28.1g/t Ag, 1.06% Pb, and 9.07% Zn and 13 metres of 8.38g/t Ag, 0.39% Pb, and 2.22% Zn. Sampling of underground workings in Yanapallaca area before the previous operators retuned 106 g/t Ag, 3.26% Pb and 17.56% Zn over 2.00 metres. (see 43-101 Technical Report on Don Pancho filed December 30th, 2014 on Sedar). Please note that the true width of the mineralization both on the surface and underground workings cannot yet be determined as the controls of the mineralization is yet to be fully understood.

A program of geophysics, diamond drilling and underground drifting is envisioned. Structural analysis on the geology suggests previous drilling did not properly test the potential of the property.

The Agreement will permit Tartisan to acquire a 100% undivided interest in the property by paying $50,000 and issuing 500,000 common shares by March 31, 2017. Upon completion of 5,000 metres of drilling and/or underground development a further 150,000 shares are payable and if a NI 43-101 compliant resource is published, a further 150,000 shares are payable and if the Company loses control of the project either by sale or joint-venture, a further 200,000 shares are payable. Duran will retain a 2% net smelter return royalty, of which half (1%) can be purchased by Tartisan for US$500,000.

Tartisan Resources Corp. common shares are listed on the Canadian Securities Exchange (CSE:TTC). Currently, there are 63,287,629 shares outstanding (82,759,982 fully diluted).

For further information on Tartisan, please contact Mr. D. Mark Appleby, President & CEO and a Director of the Company, at 416-804-0280 (mark@tartisanresources.com). Additional information about Tartisan can be found at the Company’s website at www.tartisanresources.com or on SEDAR at www.sedar.com. For further information on Duran, please contact Jeff Reeder at 647-302-3290 (info@duranventuresinc.com) or www.duranventuresinc.com

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

Jeff Reeder P.Geo. a qualified person in the context of NI 43-101 has reviewed and approved the technical content of this News Release
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/Tartisan02222017.pdf

Source: Tartisan Resources Corp. (CSE:TTC)

Namaste Announces Signing of MOU With Canopy Growth Corporation $N.ca

Posted by AGORACOM-JC at 9:37 AM on Tuesday, February 21st, 2017

Nlogo

  • MOU with Canopy Growth Corporation  (TSX:WEED), a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms
  • MOU represents the execution of Namaste’s strategic objective to actively migrate medical cannabis consumers to a licensed producer
  • Purpose of the MOU is to define the intention of Namaste and Canopy to expand their respective market positions by seeking to form multi-point working arrangements and exploring the development of new delivery devices for the consumption of cannabis

VANCOUVER, BRITISH COLUMBIA–(Feb. 21, 2017) - Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ) is pleased to announce that it has entered a memorandum of understanding (“MOU”) with Canopy Growth Corporation (“Canopy”) (TSX:WEED), a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. This MOU represents the execution of Namaste’s strategic objective to actively migrate medical cannabis consumers to a licensed producer. Namaste’s database consists of approximately 300,000 customers that generate upwards of 600,000 site visits monthly. Approximately 28,000 of these monthly site visits are generated from customers residing in Canada.

The purpose of the MOU is to define the intention of Namaste and Canopy to expand their respective market positions by seeking to form multi-point working arrangements and exploring the development of new delivery devices for the consumption of cannabis. Pursuant to the terms of the MOU, Namaste and Canopy will work together to educate Namaste’s Canada-based clients on the legal, regulated framework for medical cannabis. Namaste will also support Canopy on the development of Canopy branded vaporizers and accessories.

The commercial aspects of this partnership will be further expanded through a multi-function working group of Namaste and Canopy.

Management Commentary

Sean Dollinger, President and CEO of Namaste, comments: “Our company has successfully built one of the largest and most global client relationship databases in the cannabis industry and we view broadening our strategic alliances to the benefit of our customers and shareholders. Consistent with our strategy to partner with leading companies that hold themselves to the highest standards, Canopy represents the ideal partner for us to roll-out this strategy alongside. Going forward, we see multiple opportunities to expand this strategy globally.”

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly-owned subsidiaries, Canopy Growth operates multiple state-of the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad.

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 e-commerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the company and its products can be accessed through the link below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to several factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+ 1 (786) 389-9771
info@namastevapes.com
www.namastetechnologies.com

 

 

LBSR: Charts signal copper is about to make a powerful move $LBSR.us

Posted by AGORACOM-JC at 12:37 PM on Saturday, February 18th, 2017
  • Copper is often used as a barometer for the health of the global economy.
  • Naturally, Jim Cramer’s interest was naturally piqued when the red metal made a big breakout to the upside recently.

“Copper’s strength is part of the traditional metrics that define economic growth and it can be a part of the rational justification for what so many believe is an irrational rally,” the “Mad Money” host said.

When demand for copper increases, that means industrial activity is on the rise because copper is used to make a wide array of things from new factories, to new houses and automobiles.
However, Cramer did note that he doesn’t know if demand has increased because there have been major production cuts, which could signal the jump is supply driven rather than due to stronger demand.


To get the real deal on what the charts predict for the future of copper, Cramer spoke with technician Ed Ponsi, who is the managing director of Barchetta Capital Management and colleague at RealMoney.com.

With copper at a 12-month high and major stock indices at all-time highs, Ponsi found that history tends to make powerful moves when both stocks and copper move together.
“It is not a crystal ball. However, those who ignore history are doomed not to profit from it, so it would be a mistake to ignore copper’s latest move,” Cramer said.

What the market really loves is increased demand for copper, and most factors seem to be supply related, unfortunately. Workers are on strike at BHP Billiton‘s Escondida mine in Chile, the largest copper mine in the world. Freeport-McMoRan also cut production at its Grasberg copper mine, the third largest in the world.

However, there was one element that Ponsi thinks could be very bullish. China consumes nearly 50 percent of the world’s copper, so when its economy is on the rise, the price of copper tends to soar.

Looking at the weekly chart of copper going back to 2008, from the bottom in 2009 to the peak near 2011, the price of copper nearly tripled. Ponsi noted this was largely driven by China.

For the first time in years, there are bullish signals coming from China’s economy, as according to last week’s positive trade balance figures, exports are up 7.9 percent in January and imports up 16.7 percent.

Ponsi thinks the strength in copper could be great news for both the global economy and for U.S. stocks in particular.

“I am still a bit skeptical because if copper is only rallying because of tighter supply … then that is a lot less significant for economies around the globe,” Cramer said.

However, by traditional measures of economic strength, copper’s rally could mean good things for the future of the stock market.

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagramVine

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Source: http://www.cnbc.com/2017/02/15/cramer-charts-signal-copper-is-about-to-make-a-powerful-move.html

Durango Announces Acquisition of Bentonite, Perlite and Zeolite Projects in BC $DGO.ca

Posted by AGORACOM-JC at 5:12 PM on Thursday, February 16th, 2017

Logo

  • Acquired a 100% interest in British Columbia industrial mineral claims covering five projects which include bentonite, perlite, and zeolite BC MINFILE occurrences

Vancouver, BC / February 16, 2017 – Durango Resources Inc. (TSX.V-DGO), (the “Company” or “Durango”) is pleased to announce that it has acquired a 100% interest in British Columbia industrial mineral claims covering five projects which include bentonite, perlite, and zeolite BC MINFILE occurrences.

One zeolite project is located adjacent to the recently announced acquisition by Ashburton Ventures (TSX.V-ABR), as outlined in the Ashburton news release dated January 30, 2017. The Durango acquisition overstakes the irregular-shaped mining lease of the Z-1 zeolite quarry/mine near Cache Creek, British Columbia, being acquired by Ashburton and is within approximately 800 metres of the centre of the mining lease.

The second zeolite project is also located in the Cache Creek area, along Hwy 1/Hwy 97. Durango is acquiring 100% of an occurrence of zeolite, known as Perry Ranch, reported in 2011. The acquisition covers an area that is reported as “…approximately 300 metres long and contains several layers to 10 metres depth.” (1)

The third claim block covers the Uncha Lake perlite occurrence (2), and is located near Burns Lake, British Columbia. Past work discusses the occurrences as a perlite unit interbedded within porphyritic rhyolite layers which are reported to be 2.0 – 9.0 metres thick. The perlite is light grey to pale greenish-grey with some perlitic glass occurrences. The perlite generally dips shallowly to the south and is 7.6 to 23.9 metres thick. The report goes on to state that historical reports indicate that in 1955, nineteen trenches were exposed at approximately 45 metre intervals, exposing 2,400 metres of bedrock. Six perlite layers along a zone 850 metres long and 500 metres wide were exposed. (2) (3)

Durango is also acquiring the past-producing Princeton Bentonite occurrence, near Princeton, British Columbia, which was historically reported to have produced 771 tonnes of bentonite between 1926 and 1944. (4)

Three additional titles adjacent to the Dot Mordenite BC MINFILE occurrence near Merritt, British Columbia, which has been reported as a potential zeolite prospect, area also part of this land package. (5) (6)

Further details on these acquisitions will be provided as they become available.

About Zeolite, Perlite, and Bentonite

Zeolites are microporous aluminosilicate minerals commonly used as commercial absorbents and catalysts in the petrochemical industry as well as detergents. They are also widely used as ion-exchange beds in domestic and commercial water purification, softening, and aquaculture applications. Zeolite is also used in growing media, animal feed supplements, composting, and alternative medicine.

Perlite is an amorphous volcanic glass, typically formed by the hydration of obsidian. It has the unusual property of greatly expanding when heated sufficiently. Perlite is primarily used in construction in the production of lightweight plasters, mortars and cement formulations, and in well cements for oil and gas drilling. In horticulture, perlite can be used as a soil amendment or alone as a medium for hydroponics or for starting cuttings.

Bentonite is an absorbent aluminum phyllosilicate clay consisting mostly of montmorillonite. The main uses of bentonite are for drilling mud, binder (e.g. foundry-sand bond, iron ore pelletizer), purifier, absorbent, and as a groundwater barrier. Bentonite is also used in some forms of alternative medicine.

Durango has agreed to pay 1,000,000 common shares to an arm’s length vendor for the 100% acquisition of all projects subject to TSX Venture Exchange approval.

The technical contents of this release were approved by Case Lewis, P.Geo., a Qualified Person as defined by National Instrument 43-101. The property has not yet been the subject of a National Instrument 43-101 report.

References

  1. (1)ARIS (BC Assessment Report Database) Report 33072
  2. (2)ARIS (BC Assessment Report Database) Report 20026
  3. (3)BC MINFILE 093F 026: “UNCHA LAKE”
  4. (4)BC MINFILE 092HSE151: “PRINCETON BENTONITE”
  5. (5)BC MINFILE 092ISW108: “DOT MORDENITE”
  6. (6)ARIS (BC Assessment Report Database) Report 30607

About Durango

Durango is a natural resources company engaged in the acquisition and exploration of mineral properties. The Company has a 100% interest in the Mayner’s Fortune and Smith Island limestone properties in northwest British Columbia, the Decouverte and Trove gold properties in the Abitibi Region of Quebec, and certain lithium properties near the Whabouchi mine, the Buckshot graphite property near the Miller Mine in Quebec, the Dianna Lake silver project in northern Saskatchewan, the Whitney Northwest property near the Lake Shore Gold and Goldcorp joint venture in Ontario, as well as three sets of claims in the Labrador nickel corridor.

For further information on Durango, please refer to its SEDAR profile at www.sedar.com.

Marcy Kiesman, Chief Executive Officer

Telephone: 604.428.2900 or 604.339.2243

Facsimile: 888.266.3983

Email: durangoresourcesinc@gmail.com

Website: www.durangoresourcesinc.com

Forward-Looking Statements

This document may contain or refer to forward-looking information based on current expectations, including, but not limited to the development, commencement and completion of future exploration or project development programs and the impact on the Company of these events. Forward-looking information is subject to significant risks and uncertainties, as actual results may differ materially from forecasted results. Forward-looking information is provided as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances. For a detailed list of risks and uncertainties relating to Durango, please refer to the Company’s prospectus filed on its SEDAR profile at www.sedar.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

UPDATE: Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 2:24 PM on Thursday, February 16th, 2017

Tbp large

  • Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers

OTTAWA, ONTARIO–(Feb. 16, 2017) - PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 12:39 PM on Thursday, February 16th, 2017

Tbp large

  • Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis
  • We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

OTTAWA, ONTARIO–(Feb. 16, 2017) - PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Lithium: The Fuel of the Green Revolution $DGO.ca $FMR.ca $SX.ca $BFF.ca $NAM.ca

Posted by AGORACOM-JC at 4:26 PM on Wednesday, February 15th, 2017

Mining Minute – S2- Episode 4- Hyperloop Contest Results $KWG.ca

Posted by AGORACOM-JC at 2:48 PM on Wednesday, February 15th, 2017